{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:44:18Z","timestamp":1788475458000,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Cardiovascular Interventions"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:sec>\n            <jats:title>Background\u2014<\/jats:title>\n            <jats:p>Acute thrombogenicity and re-endothelialization represent clinically relevant end points pertaining to the safety of coronary stents, which have not been compared among biodegradable polymer-based drug-eluting metallic stents and fully bioabsorbable scaffolds to date.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Results\u2014<\/jats:title>\n            <jats:p>We investigated comparative outcomes with respect to acute thrombogenicity and re-endothelialization among thin-strut biodegradable polymer metallic everolimus eluting stents (EES), thick-strut fully bioabsorbable EES, thick-strut biodegradable polymer metallic biolimus-eluting stents and control bare metal stents. An ex-vivo porcine arterio-venous shunt model was used to assess platelet aggregation, whereas a healthy rabbit model of iliofemoral stent implantation was used to assess re-endothelialization and inflammation. Confocal microscopy was used to detect fluorescently labeled antibody staining directed against CD61\/CD42b for the identification of aggregated thrombocytes, CD14\/PM-1, and RAM-11 for identification of neutrophils and monocytes\/macrophages. Endothelial recovery was assessed by scanning electron microscopy, whereas CD31\/PECAM-1 was used to confirm endothelial maturity. EES demonstrated significantly less acute thrombogenicity compared with bioabsorbable EES and biolimus-eluting stents. EES showed greater re-endothelialization at 28 days and reduced inflammatory cell adhesion of monocytes\/macrophages at 14 days compared with bioabsorbable EES. Only bare metal stents showed complete re-endothelialization at 28 days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions\u2014<\/jats:title>\n            <jats:p>These outcomes indicate differential trends in thrombogenicity and vascular healing among contemporary stents used in clinical practice and suggest a need for long-term adjunct antithrombotic pharmacotherapy for bioabsorbable EES.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circinterventions.115.002427","type":"journal-article","created":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T02:56:40Z","timestamp":1432868200000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":111,"title":["Thrombogenicity and Early Vascular Healing Response in Metallic Biodegradable Polymer-Based and Fully Bioabsorbable Drug-Eluting Stents"],"prefix":"10.1161","volume":"8","author":[{"given":"Tobias","family":"Koppara","sequence":"first","affiliation":[{"name":"From the CVPath Institute Inc (T.K., Q.C., K.Y., H.M., O.D.S., E.W., F.D.K., R.V., M.J.), Gaithersburg, MD; and Boston Scientific Corporation (J.F.), Marlborough, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Cheng","sequence":"additional","affiliation":[{"name":"From the CVPath Institute Inc (T.K., Q.C., K.Y., H.M., O.D.S., E.W., F.D.K., R.V., M.J.), Gaithersburg, MD; and Boston Scientific Corporation (J.F.), Marlborough, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Yahagi","sequence":"additional","affiliation":[{"name":"From the CVPath Institute Inc (T.K., Q.C., K.Y., H.M., O.D.S., E.W., F.D.K., R.V., M.J.), Gaithersburg, MD; and Boston Scientific Corporation (J.F.), Marlborough, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyoshi","family":"Mori","sequence":"additional","affiliation":[{"name":"From the CVPath Institute Inc (T.K., Q.C., K.Y., H.M., O.D.S., E.W., F.D.K., R.V., M.J.), Gaithersburg, MD; and Boston Scientific Corporation (J.F.), Marlborough, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar David","family":"Sanchez","sequence":"additional","affiliation":[{"name":"From the CVPath Institute Inc (T.K., Q.C., K.Y., H.M., O.D.S., E.W., F.D.K., R.V., M.J.), Gaithersburg, MD; and Boston Scientific Corporation (J.F.), Marlborough, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Feygin","sequence":"additional","affiliation":[{"name":"From the CVPath Institute Inc (T.K., Q.C., K.Y., H.M., O.D.S., E.W., F.D.K., R.V., M.J.), Gaithersburg, MD; and Boston Scientific Corporation (J.F.), Marlborough, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wittchow","sequence":"additional","affiliation":[{"name":"From the CVPath Institute Inc (T.K., Q.C., K.Y., H.M., O.D.S., E.W., F.D.K., R.V., M.J.), Gaithersburg, MD; and Boston Scientific Corporation (J.F.), Marlborough, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank D.","family":"Kolodgie","sequence":"additional","affiliation":[{"name":"From the CVPath Institute Inc (T.K., Q.C., K.Y., H.M., O.D.S., E.W., F.D.K., R.V., M.J.), Gaithersburg, MD; and Boston Scientific Corporation (J.F.), Marlborough, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Virmani","sequence":"additional","affiliation":[{"name":"From the CVPath Institute Inc (T.K., Q.C., K.Y., H.M., O.D.S., E.W., F.D.K., R.V., M.J.), Gaithersburg, MD; and Boston Scientific Corporation (J.F.), Marlborough, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Joner","sequence":"additional","affiliation":[{"name":"From the CVPath Institute Inc (T.K., Q.C., K.Y., H.M., O.D.S., E.W., F.D.K., R.V., M.J.), Gaithersburg, MD; and Boston Scientific Corporation (J.F.), Marlborough, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.03.042"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.693739"},{"key":"e_1_3_3_4_2","first-page":"473","article-title":"Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging.","volume":"60","author":"Byrne RA","year":"2012","unstructured":"Byrne RA, Joner M, Tada T, Kastrati A. Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging. Minerva Cardioangiol. 2012;60:473\u2013489.","journal-title":"Minerva Cardioangiol"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60324-9"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61223-9"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.003210"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61672-3"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs086"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61455-0"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2009.09.079"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.17226\/25801"},{"key":"e_1_3_3_13_2","first-page":"383","article-title":"Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents.","volume":"25","author":"Yazdani SK","year":"2013","unstructured":"Yazdani SK, Sheehy A, Nakano M, Nakazawa G, Vorpahl M, Otsuka F, Donn RS, Perkins LE, Simonton CA, Kolodgie FD, Virmani R. Preclinical evaluation of second-generation everolimus- and zotarolimus-eluting coronary stents. J Invasive Cardiol. 2013;25:383\u2013390.","journal-title":"J Invasive Cardiol"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-042192"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-331579"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.113.000120"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.12.2995"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.02.607"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081501"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)98003-4"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.5.2311"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.1.170"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.04.030"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-925X-5-40"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.632687"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1615\/JLongTermEffMedImplants.v10.i12.120"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2013.10.015"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067731"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","unstructured":"Kufner S Byrne RA Valeskini M Schulz S Ibrahim T Hoppmann P Schneider S Laugwitz KL Schunkert H Kastrati A. Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial [published online ahead of print November 12 2014]. EuroIntervention. doi: 10.4244\/EIJY14M11_02.","DOI":"10.4244\/EIJY14M11_02"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2013.04.011"},{"key":"e_1_3_3_31_2","unstructured":"Ielasi A Cortese B Varricchio A Tespili M Sesana M Pisano F Loi B Granata F Moscarella E Silva Orrego P La Vecchia L Steffenino G. Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: insights from the multicentre \u201cRegistro ABSORB Italiano\u201d (RAI registry) [published online ahead of print October 30 2014]. EuroIntervention. doi 10.4244\/EIJY14M10_11."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV9I9A176"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV9I4A80"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJY14M07_11"}],"container-title":["Circulation: Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCINTERVENTIONS.115.002427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T02:32:05Z","timestamp":1715567525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCINTERVENTIONS.115.002427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1161\/CIRCINTERVENTIONS.115.002427"],"URL":"https:\/\/doi.org\/10.1161\/circinterventions.115.002427","relation":{},"ISSN":["1941-7640","1941-7632"],"issn-type":[{"value":"1941-7640","type":"print"},{"value":"1941-7632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"2015-01-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-05-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}